<DOC>
	<DOCNO>NCT00998751</DOCNO>
	<brief_summary>The objective evaluate efficacy safety AB1010 7.5 mg/kg/day treatment non pre-treated , inoperable patient locally advanced/metastatic GIST .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Efficacy Safety Masitinib Non Pre-treated , Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour ( GIST )</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>Male Female patient , age &gt; 18 Life expectancy &gt; 6 month Histological proven , metastatic , locally advance nonoperable , non pretreated GIST . Patients never receive tyrosine kinase inhibitor , include adjuvant therapy CKit ( CD117 ) positive tumor detect immunohistochemically Measurable tumor lesion longest diameter &gt; 20 mm use conventional technique &gt; 10 mm spiral CT scan Documented allergy similar drug AB1010 Inadequate organ function Patients history malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>cKIT inhibitor</keyword>
	<keyword>GIST</keyword>
</DOC>